Immunovant (Nasdaq: IMVT) reported that its FcRn inhibitor imeroprubart (IMVT-1402) failed to meet the primary endpoint in a proof-of-concept trial in cutaneous lupus erythematosus (CLE), and said it will discontinue development in the indication.
The randomized, double-blind, placebo-controlled study enrolled 57 adults with CLE and assessed the percent change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score at Week 12. The trial did not achieve statistical significance on that primary endpoint. Numerical trends favoring imeroprubart over placebo were observed across multiple endpoints, and patients who achieved deeper IgG reductions from baseline were more likely to achieve improved clinical responses, but no specific numerical values were disclosed.
Imeroprubart is a subcutaneously administered monoclonal antibody that antagonizes the neonatal Fc receptor (FcRn), producing dose-dependent reductions in circulating IgG in patients with IgG-mediated autoimmune diseases. The drug demonstrated a favorable safety and tolerability profile consistent with prior studies. Immunovant cited both the clinical results and the competitive landscape as the basis for its decision to stop development in CLE.
The CLE competitive landscape includes several late-stage programs with mechanisms distinct from FcRn inhibition. Biogen reported positive Phase II data for its anti-BDCA2 antibody litifilimab in March 2026, while Merck KGaA has begun the Phase III ELOWEN program of oral TLR7/8 inhibitor enpatoran in lupus patients with active cutaneous manifestations. No therapy is currently approved by the FDA or EMA specifically for CLE.
Johnson & Johnson has demonstrated that FcRn blockade has activity in systemic lupus erythematosus, reporting a Phase II win for nipocalimab (Imaavy) in that indication and advancing into a pivotal program, but CLE has not emerged as a primary focus for the FcRn class.